Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesar A Santa-Maria

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.
JCO Oncology Practice|September 21, 2023
Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone AppKaren Lisa Smith, Hua-Ling Tsai, David Lim, et al.
JCO Oncology Practice|July 1, 2020
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific ApproachJennifer Y Sheng, Cesar A Santa-Maria, Neha Mangini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote TrialCesar A Santa-Maria, Janelle W Coughlin, Dipali Sharma, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkersJarushka Naidoo, Karisa C Schreck, Wei Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation OncologistsAlice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2015
Association of Variants in Candidate Genes with Lipid Profiles in Women with Early Breast Cancer on Adjuvant Aromatase Inhibitor TherapyCesar A Santa-Maria, Amanda Blackford, Anne T Nguyen, et al.
JAMA Oncology|December 14, 2023
Atezolizumab in Combination With Carboplatin and Survival Outcomes in Patients With Metastatic Triple-Negative Breast Cancer: The TBCRC 043 Phase 2 Randomized Clinical TrialBrian D Lehmann, Vandana G Abramson, E Claire Dees, et al.
Breast Cancer Research and Treatment|May 13, 2018
A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trialCesar A Santa-Maria, Aditya Bardia, Amanda L Blackford, et al.
JCO Oncology Practice|September 21, 2023
Feasibility of Symptom Monitoring During the First Year of Endocrine Therapy for Early Breast Cancer Using Patient-Reported Outcomes Collected via Smartphone AppKaren Lisa Smith, Hua-Ling Tsai, David Lim, et al.
JCO Oncology Practice|July 1, 2020
Management of Breast Cancer During the COVID-19 Pandemic: A Stage- and Subtype-Specific ApproachJennifer Y Sheng, Cesar A Santa-Maria, Neha Mangini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2020
The Effects of a Remote-based Weight Loss Program on Adipocytokines, Metabolic Markers, and Telomere Length in Breast Cancer Survivors: the POWER-Remote TrialCesar A Santa-Maria, Janelle W Coughlin, Dipali Sharma, et al.
Journal for Immunotherapy of Cancer|August 12, 2021
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkersJarushka Naidoo, Karisa C Schreck, Wei Fu, et al.
International Journal of Radiation Oncology, Biology, Physics|May 18, 2020
Optimizing Radiation Therapy to Boost Systemic Immune Responses in Breast Cancer: A Critical Review for Breast Radiation OncologistsAlice Y Ho, Jean L Wright, Rachel C Blitzblau, et al.
Cancer Discovery|October 4, 2023
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast CancerBrandie C Taylor, Xiaopeng Sun, Paula I Gonzalez-Ericsson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2020
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related GenesNadine M Tung, Mark E Robson, Steffen Ventz, et al.
Pageof 6